Excellence in Research & Development
CSL's mission is to discover, develop and deliver our innovative therapies that improve the patients' quality of life. Our scientists and researchers are recognized for their contributions to developing breakthrough medicines that have the potential to help millions of patients worldwide.
We are grateful to the patients, volunteers and researchers that participate in the clinical trials for testing our potential biotherapies. All contributions have helped better our understanding of diseases.
CSL's R&D capabilities are focused in four major areas:
CSL’s clinical research activities make products available to patients worldwide and identify novel therapeutic uses for plasma proteins.
As a leading manufacturer and developer of therapeutics derived from human plasma, CSL is committed to maintaining the highest product safety standards and to continually improving manufacturing effectiveness. CSL's research programs are focused on developing novel plasma proteins with improved efficacy and enhanced convenience.
We have extensive experience in the production, clinical development and launch of recombinant coagulation factors.
We are also developing expertise to support the production and testing of new recombinant proteins, including monoclonal antibodies (MAbs) to treat inflammation.
Through the recent acquisition of Calimmune, Inc. CSL is now focused on the development of ex vivo hematopoietic stem cell (HSC) gene therapy which has the potential to offer a significant advantage to patients suffering from currently incurable genetic diseases.
The recent acquisition of Calimmune introduces CAL-H to our pipeline, an HSC gene therapy for the treatment of sickle cell disease and β-thalassemia, which complements our current product portfolio and deep expertise in hematology.
The technology also has the potential to be used in treatments for a wide range of other rare diseases that would complement our business, including those within the company’s current product portfolio.
Seqirus has leading R&D capabilities and a broad portfolio of differentiated products with commercial operations in over 20 countries. Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally.
These capabilities manifest themselves in our innovative immunoglobulins, specialty plasma products, hemophilia products, breakthrough medicines, treatments for transplant and vaccines.
R&D provides support to CSL's world-leading immunoglobulin (Ig) franchise. Our efforts in this area are focused on new indications for our existing intravenous and subcutaneous products such as Hizentra® and Privigen®, exploring new molecules and new technologies for delivery options, focusing on new indications for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and refining our formulation and purification processes.
We recently announced an exclusive research collaboration and worldwide licence agreement with Momenta Pharmaceuticals, Inc. to develop and commercialize their recombinant Fc multimer proteins for use in controlling inflammation. The agreement includes Momenta’s novel M230 product, which has been shown to match the potency and efficacy of intravenous Ig at significantly lower doses in animal models of autoimmune disease.
Hemophilia & Coagulation Products
R&D has contributed to major advancements in recent years with the launches of CSL's internally developed family of novel recombinant coagulation factor medicines, including AFSTYLA® and IDELVION®. Our hemophilia research strategy is based on maximizing the value and performance of our existing coagulation therapies and developing new protein-based therapies for treating bleeding disorders - all with a major focus on increasing the patient quality of life.
CSL Behring recently launched HAEGARDA®, the world's first and only subcutaneous preventative treatment for Hereditary Angioedema (HAE). Significant work is underway to further unlock the medical significance and value of CSL's specialty plasma-derived products for the treatment of Alpha-1 antitrypsin deficiency, and a therapy that reverses the effects of vitamin K antagonists (e.g. warfarin) for bleeding related to over-anticoagulation and patients needing urgent surgery.
CSL is committed to developing therapies for patients with rare and life-threatening conditions. We are currently developing new products in solid organ transplant, an area of unmet clinical need. Organ transplants often fail and the organ is eventually rejected, even though the transplant has been successful in the first instance. CSL is trialing the use of existing immunodeficiency and inflammation therapies including PRIVIGEN® to improve these outcomes.
We recently entered into a strategic collaboration with Vitaeris Inc. to expedite the development of clazakizumab (an anti-IL6 MAB, formerly ALD518) as a therapeutic option for solid organ transplant rejection. Vitaeris' transplant rejection program is complementary to CSL's current development activities in solid organ transplant.
Seqirus, the world's second largest influenza vaccine provider , has a portfolio including several late stage projects, mostly involving the development of quadrivalent versions to replace/supplement trivalent vaccines. All seasonal and pandemic influenza vaccine projects are either in Phase III or registration/launch. Seqirus have also introduced cell-based technology to manufacture cell-culture vaccines to augment egg-based vaccines.
R&D leverages its clinical and technical insights to develop breakthrough protein-based therapies that address a significant unmet need. Currently in the pipeline, CSL has novel therapies aimed at reducing the high incidence of early recurrent cardiovascular events in the days and weeks following a heart attack (CSL112). We are also developing novel monoclonal antibodies. They include a human antibody (CSL324) that neutralizes G-CSF activity for the treatment of inflammatory diseases; and a diabetes treatment (CSL346) that controls the uptake of fatty acids.